LPL Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10,740
| Closed | -$19.9K | – | 4743 |
|
|
2023
Q1 | $19.9K | Hold |
10,740
| – | – | ﹤0.01% | 4411 |
|
|
2022
Q4 | $11.9K | Sell |
10,740
-14,375
| -57% | -$20.5K | ﹤0.01% | 4407 |
|
|
2022
Q3 | $59K | Sell |
25,115
-600
| -2% | -$2.13K | ﹤0.01% | 4213 |
|
|
2022
Q2 | $78K | Sell |
25,715
-13,997
| -35% | -$68.1K | ﹤0.01% | 4174 |
|
|
2022
Q1 | $270K | Buy |
39,712
+2,277
| +6% | +$16.2K | ﹤0.01% | 3645 |
|
|
2021
Q4 | $313K | Sell |
37,435
-250
| -0.7% | -$2.06K | ﹤0.01% | 3656 |
|
|
2021
Q3 | $280K | Buy |
37,685
+250
| +0.7% | +$1.55K | ﹤0.01% | 3712 |
|
|
2021
Q2 | $255K | Sell |
37,435
-2,050
| -5% | -$17K | ﹤0.01% | 3723 |
|
|
2021
Q1 | $406K | Sell |
39,485
-1,775
| -4% | -$19.4K | ﹤0.01% | 3207 |
|
|
2020
Q4 | $289K | Sell |
41,260
-1,275
| -3% | -$9.92K | ﹤0.01% | 3228 |
|
|
2020
Q3 | $347K | Sell |
42,535
-660
| -2% | -$4.09K | ﹤0.01% | 2791 |
|
|
2020
Q2 | $298K | Buy |
43,195
+465
| +1% | +$2.51K | ﹤0.01% | 2840 |
|
|
2020
Q1 | $203K | Buy |
42,730
+15,890
| +59% | +$91.5K | ﹤0.01% | 2799 |
|
|
2019
Q4 | $234K | Buy |
26,840
+4,045
| +18% | +$21.9K | ﹤0.01% | 2980 |
|
|
2019
Q3 | $76K | Buy |
+22,795
| New | +$91.3K | ﹤0.01% | 3174 |
|
Other funds holding JNCE
LPL Financial's JNCE Position: Q2 2023 in Review
LPL Financial sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 10,740 shares — an estimated $19.9K sold.
LPL Financial first reported a position in JNCE in Q3 2019 and held it in 15 quarters. The position peaked at $406K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- LPL Financial reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- LPL Financial sold 10,740 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $19.9K.
- LPL Financial first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- LPL Financial's Jounce Therapeutics, Inc. Common Stock position peaked at $406K in Q1 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on LPL Financial's 13F filing for Q2 2023, filed 31 Jul 2023.